Latest Selexis SA Stories
Selexis SA Is the First Biotechnology Company to Deliver Manufacturing-Ready Research Cell Banks with a Fully Sequenced Genome and Transcriptome Geneva, Switzerland
Selexis SA announced today the first therapeutic biologic generated with the Selexis SUREtechnology Platform™ has been approved for market. Geneva, Switzerland
Symphogen has licensed the rights to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the development of recombinant monoclonal antibody (MAb) mixtures for the treatment
Selexis has promoted director of European business development, Marco Bocci, PhD, PharmD, to Vice President, European Licensing and Business Development for Europe. Geneva,
ReportsnReports.com adds "Cell Line Development Market by Product (Equipment, Media and Reagents), Source, type & by Application (Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity
Data addresses key issues associated with effective translation, translocation and secretion of therapeutic proteins in mammalian cell lines Geneva, Switzerland
Selexis to Meet with Biopharmaceutical Companies Interested in Protein Drug Discovery, Mammalian Cell Line Development and Lead Identification for Therapeutic Drug Development and Manufacturing
Company CSO to Present Data on the Selexis SURE CHO-Mplus™ Libraries Geneva, Switzerland (PRWEB) April 23, 2014 Selexis SA, a serial innovation company
- a study of the individuals in a group of people within a specific context and their relationships.
- In rhetoric, the description of any one's personal appearance.